Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltratio...( NEW YORK June 6 /- Nephros Inc. (...),Health

NEW YORK, June 6 /PRNewswire-FirstCall/ -- Nephros, Inc. (Amex: NEP), a medical device company, announced today that it has completed the pivotal U.S. clinical trial for its OLpur(TM) H2H module and OLpur(TM) MD220 filter for End Stage Renal Disease (ESRD) therapy.

"We're excited and pleased to have reached this important milestone. There is a broad range of literature supporting the advantages of hemodiafiltration (HDF) over dialysis for the ESRD patient, including studies supporting a substantial reduction in the relative risk of mortality. While HDF is prevalent in Europe, no on-line HDF system has yet been approved for use in the U.S. We believe our mid-dilution HDF technology can offer a vital advance in therapy to U.S. ESRD patients," said Norman Barta, Nephros' CEO.

Nephros is now in the process of preparing its submission to the Food and Drug Administration under section 510(k) of the Food, Drug and Cosmetics Act to obtain approval to sell its mid-dilution HDF products in the U.S. If timely approved, Nephros believes its products will be the first on-line HDF products available to ESRD clinics and patients in the U.S.

About Nephros, Inc.

Nephros, Inc., headquartered in New York, is a medical device company developing and marketing products in End Stage Renal Disease (ESRD) therapy and water ultrafiltration.

ESRD is a disease state characterized by the irreversible loss of kidney function. Nephros' HDF products are designed to improve the quality of life for the ESRD patient, while addressing the critical financial and clinical needs of the care provider. The OLpur(TM) H2H is an add-on module that allows the most common types of hemodialysis machines to be used for on-line HDF therapy. The OLpur(TM
'/>"/>